MedElevator
Войти в исследования Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Duarte-Salles Talita, Vizcaya David, Pistillo Andrea, Casajust Paula, Sena Anthony G, Lai Lana Yin Hui, Prats-Uribe Albert, Ahmed Waheed-Ul-Rahman, Alshammari Thamir M, Alghoul Heba, Alser Osaid, Burn Edward, You Seng Chan, Areia Carlos, Blacketer Clair, DuVall Scott, Falconer Thomas, Fernandez-Bertolin Sergio, Fortin Stephen, Golozar Asieh, Gong Mengchun, Tan Eng Hooi, Huser Vojtech, Iveli Pablo, Morales Daniel R, Nyberg Fredrik, Posada Jose D, Recalde Martina, Roel Elena, Schilling Lisa M, Shah Nigam H, Shah Karishma, Suchard Marc A, Zhang Lin, Zhang Ying, Williams Andrew E, Reich Christian G, Hripcsak George, Rijnbeek Peter, Ryan Patrick, Kostka Kristin, Prieto-Alhambra Daniel
Аннотация
METHODS: International network cohort using real-world data from European primary care records (France, Germany, and Spain), South Korean claims and US claims, and hospital databases. We included children and adolescents diagnosed and/or hospitalized with COVID-19 at age <18 between January and June 2020. We described baseline demographics, comorbidities, symptoms, 30-day in-hospital treatments, and outcomes including hospitalization, pneumonia, acute respiratory distress syndrome, multisystem inflammatory syndrome in children, and death.
RESULTS: A total of 242 158 children and adolescents diagnosed and 9769 hospitalized with COVID-19 and 2 084 180 diagnosed with influenza were studied. Comorbidities including neurodevelopmental disorders, heart disease, and cancer were more common among those hospitalized with versus diagnosed with COVID-19. Dyspnea, bronchiolitis, anosmia, and gastrointestinal symptoms were more common in COVID-19 than influenza. In-hospital prevalent treatments for COVID-19 included repurposed medications (<10%) and adjunctive therapies: systemic corticosteroids (6.8%-7.6%), famotidine (9.0%-28.1%), and antithrombotics such as aspirin (2.0%-21.4%), heparin (2.2%-18.1%), and enoxaparin (2.8%-14.8%). Hospitalization was observed in 0.3% to 1.3% of the cohort diagnosed with COVID-19, with undetectable (n < 5 per database) 30-day fatality. Thirty-day outcomes including pneumonia and hypoxemia were more frequent in COVID-19 than influenza.
CONCLUSIONS: Despite negligible fatality, complications including hospitalization, hypoxemia, and pneumonia were more frequent in children and adolescents with COVID-19 than with influenza. Dyspnea, anosmia, and gastrointestinal symptoms could help differentiate diagnoses. A wide range of medications was used for the inpatient management of pediatric COVID-19.